“We look forward to presenting preclinical data at ASGCT that underscore the potential of our in vivo HSC engineering platform to address complex genetic disorders and cancer,” said Robert Peters, ...
Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON, September 22, 2025--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results